TroyGould Represents Galena in $38 Million Public Offering of Common Stock and Warrants

TroyGould PC represented Galena Biopharma, Inc., a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, in connection with its underwritten public offering of 24,358,974 shares of common stock, and warrants to purchase an aggregate of 12,179,487 shares of common stock. The shares of common stock and warrants were sold in units, with each unit consisting of one share of common stock and a warrant to purchase 0.5 of a share of common stock. Each unit was sold at a price of $1.56 per unit, for aggregate gross proceeds of approximately $38 million. The underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of 1,826,923 shares of common stock. The offering closed on March 18, 2015

TroyGould members Dale Short, Darren Freedman and Marc Brown handled the transaction.